# AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

> **NCT03971747** · PHASE1 · UNKNOWN · sponsor: **Shanghai AbelZeta Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** AFP Specific T Cell Receptor T Cells

## Key facts

- **NCT ID:** NCT03971747
- **Lead sponsor:** Shanghai AbelZeta Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-06
- **Primary completion:** 2020-06
- **Final completion:** 2021-04
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2020-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971747, "AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03971747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*